Phathom's 15min chart triggered KDJ Golden Cross, bullish Marubozu pattern.

Phathom's 15-minute chart has recently triggered a KDJ Golden Cross and a Bullish Marubozu, which occurred on June 27, 2023 at 11:45. This indicates that the momentum of the stock price is shifting towards the upside and has the potential to further increase. The presence of buyers controlling the market suggests that bullish momentum is likely to continue.

Phathom Pharmaceuticals (NASDAQ: PHAT) stock experienced a significant jump last week following the U.S. Food and Drug Administration's (FDA) positive response regarding the company's novel gastric acid-reducing drug, VOQUEZNA. The FDA granted VOQUEZNA regulatory exclusivity through 2032, providing the drug with full 10-year patent protection as a new chemical entity.

The decision by the FDA highlights the potential of VOQUEZNA in the multi-billion dollar U.S. proton pump inhibitor (PPI) market. VOQUEZNA, a potassium-competitive acid blocker (PCAB), offers several advantages over traditional PPIs, including rapid and potent acid suppression, sustained 24-hour heartburn relief, and efficacy in GERD patients not responding to traditional PPIs. The drug has shown a 93% esophageal healing rate at 8 weeks, outperforming traditional PPI-based regimens in treating H. Pylori infections, especially in clarithromycin-resistant cases.

Phathom Pharmaceuticals' stock price chart indicates a shift in momentum towards the upside, as evidenced by a KDJ Golden Cross and a Bullish Marubozu on June 27, 2023. This suggests that the stock's price is likely to continue its upward trajectory, with buyers controlling the market and indicating bullish momentum.

The company's financials reflect strong growth potential. Revenue for the last 12 months was $81.9 million, with Q1 2025 revenue reaching $28.5 million, an impressive increase from $1.9 million in Q1 2024. The gross margin in Q1 2025 was $24.8 million, with a gross margin of 87%. Consensus analyst revenue estimates for 2025 are $160 million, indicating robust growth expectations.

Phathom Pharmaceuticals' discounted cash flow (DCF) valuation suggests a fair value of equity at approximately $1 billion, with an estimated fair value of the stock at $14/share, representing a 43% upside potential. The company's strong pipeline, including an orally disintegrating tablet formulation for pediatrics use and a Phase 2 trial for eosinophilic esophagitis, further enhances its growth prospects.

Near-term catalysts include the upcoming quarterly earnings report on August 14, 2025, and the potential entry into the lucrative EU market. The company's strong management team, led by CEO and President Basta with 25+ years of leadership experience in biopharma and biotech, also adds confidence in the company's ability to execute its growth strategy.

However, risks associated with the investment include competition in the crowded GERD market, the company's unprofitability, and its dependence on a single product for future revenue.

References:
[1] https://seekingalpha.com/article/4797079-phathom-pharmaceuticals-potential-blockbuster-gastric-acid-reducing-drug